Evidence-Based Therapy for Heart Failure

Medical Clinics of North America

Volumn 96, Issue 5, 2012, Pages 915-931

  Deedwania, Prakash C ^a,b   Carbajal, Enrique ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Evidence based therapy; Heart failure; Left ventricular dysfunction; Treatment

Indexed keywords

ALDOSTERONE ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CANDESARTAN; CAPTOPRIL; CARVEDILOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; EPLERENONE; FOSINOPRIL; HYDRALAZINE PLUS ISOSORBIDE DINITRATE; LISINOPRIL; LOSARTAN; METOPROLOL SUCCINATE; PERINDOPRIL; PLACEBO; QUINAPRIL; RAMIPRIL; SPIRONOLACTONE; TRANDOLAPRIL; VALSARTAN; VASODILATOR AGENT;

ANGIONEUROTIC EDEMA; COUGHING; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; EVIDENCE BASED MEDICINE; HEART FAILURE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HOSPITALIZATION; HUMAN; HYPERKALEMIA; HYPOTENSION; KIDNEY DYSFUNCTION; LEFT VENTRICULAR SYSTOLIC DYSFUNCTION; MORBIDITY; MORTALITY; PRACTICE GUIDELINE; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; VASOCONSTRICTION;

ADRENERGIC BETA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; EVIDENCE-BASED MEDICINE; HEART FAILURE; HOSPITALIZATION; HUMANS; RENIN-ANGIOTENSIN SYSTEM; VASODILATOR AGENTS; VENTRICULAR DYSFUNCTION, LEFT;

EID: 84866169617     PISSN: 00257125     EISSN: 15579859     Source Type: Journal    
DOI: 10.1016/j.mcna.2012.07.010     Document Type: Review

References (21)

1. Hunt S.A., Abraham W.T., Chin M.H., et al. 2009 Focused update incorporated into the ACC/AHA 2005 guidelines for the diagnosis and management of heart failure in adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2009, 119:e391-e479.
2. Lindenfeld J., Albert N.M., Boehmer J.P., et al. HFSA 2010 comprehensive heart failure practice guideline. J Card Fail 2010, 16:e1-e194.
3. CONSENSUS Trial Study Group: effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987, 316:1429-1435.
4. SOLVD investigators: effect on enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991, 325:293-302.
5. SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992, 327:685-691.
6. Pfeffer M., Braunwald E., Moye L., et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med 1992, 327:669-677.
7. Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993, 342:821-828.
8. Køber L., Torp-Pedersen C., Carlsen J.E., et al. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group. N Engl J Med 1995, 333(25):1670-1676.
9. Ambrosioni E., Borghi C., Magnani B. The effect of the angiotensin-converting-enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. The Survival of Myocardial Infarction Long-Term Evaluation (SMILE) Study Investigators. N Engl J Med 1995, 332(2):80-85.
10. Granger C., McMurray J., Yusuf S., et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet 2003, 362:772-776. CHARM Investigators and Committees.
11. Pitt B., Zannad F., Remme W.J., et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999, 341(10):709-717.
12. Pitt B., Remme W., Zannad F., et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003, 348(14):1309-1321. Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators.
13. Zannad F., McMurray J., Krum H., et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 2011, 364:11-21. EMPHASIS-HF Study Group.
14. Packer M., Bristow M.R., Cohn J.N., et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med 1996, 334:1349-1355.
15. Packer M., Coats A.J., Fowler M.B., et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001, 344:1651-1658. Carvedilol Prospective Randomized Cumulative Survival Study Group (COPERNICUS).
16. CIBIS-II investigators and committees: the Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): A randomized trial. Lancet 1999, 353:9-13.
17. Effect of metoprolol CR/XL in chronic heart failure: metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999, 353:2001-2007.
18. A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. N Engl J Med 2001, 344:1659-1667. Beta-Blocker Evaluation of Survival Trial Investigators.
19. Poole-Wilson P., Swedberg K., Cleland J., et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet 2003, 362:7-13. COMET investigators.
20. Taylor A.L., Ziesche S., Yancy C., et al. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med 2004, 351(20):2049-2057. African-American Heart Failure Trial Investigators.
21. Fonarow G., Yancy C., Hernandez A., et al. Potential impact of optimal implementation of evidence-based heart failure therapies on mortality. Am Heart J 2011, 161:1024-1030.e3.